Charles Lin is a Principal at Illumina Ventures and serves as a Board Observer for Iambic Therapeutics and NanoCellect Biomedical, Inc. With extensive experience in corporate and business development, they previously held the role of VP of Business Development and Marketing at Element Biosciences. Lin played a significant role in mergers and acquisitions at Illumina, including leading the $100M acquisition of Edico Genome, and contributed to critical oncology programs and high-resolution typing products. They earned a Ph.D. in Biochemistry and Molecular Biology from Harvard University and completed a postdoctoral fellowship at the Howard Hughes Medical Institute/UC San Diego.
This person is not in the org chart
This person is not in any teams
This person is not in any offices